31 results about "Vaginal epithelium" patented technology

The invention relates to an expandable vaginal suppository which comprises a first expansion carrier; a stype layer comprising active constituents and a matrix is used for at least covering an end part of the first expansion carrier; the vaginal suppository is expanded in a water solution with the pH value of 3.0-8.0 according to the predetermined expansion value; and the expansion value of the first expansion carrier in the saturated water absorption process is 1-30. The vaginal suppository can be fully and selectively contacted with vaginal epithelium and mucosal wall, the bioavailability of active drugs is averagely improved by 20-40%, and different positions of a suppository body can be expanded to different degree, so that the problem of low possibility of cleaning a sliver vaginal suppository is thoroughly solved and the problems of poor user compliance, strong discomfort and the like are avoided.

The invention belongs to the field of biomedicines and discloses a construction method and application of a human normal vaginal epithelium 3D (Three Dimensional) differentiation culture model. A 2D (Two Dimensional) growth culture medium is provided and normal vaginal epithelial cells separated and cultured from normal tissues beside female vaginal cancer are obtained; any exogenous gene is not introduced and the normal vaginal epithelial cells have a physiological function of normal differentiation. The method for constructing the human normal differentiation vaginal epithelium 3D model comprises the following steps: re-suspending single cells by the 2D culture medium and inoculating the single cells into a gas-liquid culture device; replacing the growth culture medium with a differentiation culture medium and culturing for 14 to 21 days; after completely differentiating 3D gas-liquid culture of the human vaginal epithelial cells, inoculating HSV-2 (Herpes Simplex Virus-2) virus liquid to obtain an HSV-2 virus infection 3D model. The two types of 3D models can be used for physiological studies and drug toxicity safety evaluation of human normal reproductive tract epithelium, researches of pathogenic mechanisms of HSV-2 virus infected diseases and sexual transmission pathogen infected diseases and researches and development of anti-viruses medicines.

The invention discloses lactobacillus jensenii and application thereof. The lactobacillus jensenii is particularly lactobacillus jensenii IMJ-1, and the file No. of the lactobacillus jensenii IMJ-1 in the General Microbiological Culture Collection Center of China Microbial Culture Collection Management Committee is CGMCC No. 6558. The lactobacillus jensenii IMJ-1 CGMCC No.6558 has high H2O2 generation capability, can effectively suppress breeding of external pathogenic bacteria and other conditional pathogenic bacteria, and has a high binding function to epithelial cells of vagina, and accordingly, breeding of bacteria strains on the vaginal epithelium is guranteed. Besides, the lactobacillus jensenii IMJ-1 CGMCC No. 6558 has a certain application prospect in preventing and curing bacterial vaginosis.

This invention provides devices and methods for remodeling the female genital tissue, the device comprising a treatment tip, wherein the distal end of the treatment tip is conical, spherical, hemispherical, oval or circular in shape. The device further comprises one or more energy delivery elements for simultaneous cooling of the vaginal epithelium and transmission of energy for heating the tissues underneath the epithelium. In one embodiment, said device may further comprise one or more of the following: one or more temperature sensors for measuring the temperature at or below the epithelium; one or more directional sensors mounted on the hand piece or treatment tip; and one or more depth markers to show the depth of penetration of the treatment tip into the vagina. In another embodiment, this invention provides a device having a finger holder with electrodes for remodeling the female genital tissue.

The invention discloses lactobacillus crispatus Lcr-MH175 for preventing and treating female urogenital tract infection. The preservation number of the Lcr-MH175 is CGMCC No. 15938. The lactobacilluscrispatus Lcr-MH175 provided by the invention has relatively strong antibacterial ability, can effectively inhibit growth of external pathogenic bacteria and pathogenic bacteria under other conditions, and also has a relatively strong adhesion effect on Hela cells so as to ensure the colonization of the strain on vaginal epithelium. The lactobacillus crispatus Lcr-MH175 provided by the invention has a certain application prospect in the aspect of urogenital tract infection prevention and treatment.

The invention discloses lactobacillus curvatus and pharmaceutical application thereof. The lactobacillus curvatus provided by the invention specifically is lactobacillus curvatus IMC-79 which has a relatively strong capability of generating H2O2 and can effectively inhibit the growth of external pathogenic bacteria and other conditioned pathogens; and meanwhile, the lactobacillus curvatus IMC-79 also has a relatively strong effect of adhering vaginal epithelial cells to ensure that a strain is fixedly planted on the vaginal epithelium. The lactobacillus curvatus IMC-79 provided by the invention has a certain application prospect in the aspect of preventing and treating bacterial vaginal diseases.

Methods and apparatuses for vaginal rejuvenation are provided. A method of vaginal rejuvenation includes providing an injectable solution of amniotic membrane allograft. The solution is injected into a human female in a plurality of locations in a vaginal canal and introitus area to a depth immediately below a vaginal epithelium. A speculum includes at least one longitudinal member extending from an opening along a longitudinal axis and having a wall that curves about the axis having an inner surface and an outer surface, wherein the longitudinal member comprises multiple spaced portals extending through the wall. A kit includes the speculum and the injectable solution of amniotic membrane allograft.

An efficient, safe, and reproducible surgical technique for the treatment of female stress urinary incontinence, in which the anchor consists of removable string so that no string remains inside the body after positioning, fixation and adjustment of the sling in the target place during surgery and thus minimizing the subjects discomfort after placement of the sling. Thus allowing removal of the string from the passage of the anchor for short sling system. The short and long sling system further comprises fixation of the bearing, ring and the attachment that allows for anti-twisting element to provide better flexible attachment of the sling with the delivery device facilitating relative rotational motion of the bearing with the ring and the attachment but preventing axial displacement of the bearing with the attachment. [0035] The invention further contains a device which allows attachment of the sling with the delivery device by threading / screwing during assembly. This invention relates to a method of placing the sling in a position beneath the urethra by transobturator approach using small incision through the marked position at the vaginal epithelium, beneath the level of mid-urethra, as per standard procedure for a midurethral sling for inside-out approach and making a thigh incision at the marked position, placing the sling beneath the mid-urethra through transobturator approach outside-in approach. This procedure involves for both long sling system and short sling system.

The invention discloses a culturing method of combined sequential cell in the culturing technique scale of human vaginal epithelial cell, which is characterized by the following: adopting non-serum culture medium and serum culture medium to do sequential culture; breeding human vaginal epithelial cell rapidly; improving successful generation rate at 80%.

The invention discloses lactobacillus.crispatus for preventing female urogenital tract infection. The lactobacillus.crispatus specifically refers to lactobacillus.crispatus IMC-25. The lactobacillus.crispatus IMC-25 has higher anti-bacterial capacity, can effectively inhibit growth of extraneous pathogenic bacteria and other conditioned pathogens, also has higher adhesive function on vaginal epithelial cells and guarantees colonization of strains on vaginal epitheliums. The lactobacillus.crispatus IMC-25 has certain application prospect in the aspect of prevention of urogenital tract infection.

The invention provides gynecological gel and a preparation method thereof.The gynecological gel comprises exosome, gel, sophocarpidine, berberine and a fructus cnidii extracting solution, the exosome is obtained through cell secretion, contains multiple cell factors such as EGF, can play a composite role in cell repairing, can repair damaged vaginal epithelial cells, and is free of toxic and side effects. Matrine, berberine and fructus cnidii are antibacterial and anti-inflammatory traditional Chinese medicines. The gel does not have pungent smell, is viscous, has good water solubility and adhesion, can be well adsorbed into the female vagina, has a neutral pH value, slowly reduces the viscosity of the gel in an acidic vaginal environment, gradually releases the coated exosome and traditional Chinese medicine components, and covers damaged vaginal tissues. The vagina inflammation can be effectively controlled and treated through the traditional Chinese medicine components, the exosome can act on damaged vagina epithelium to promote repair of epithelial cells, and the gel is attached to a diseased region, so that the effect of protecting a wound surface is achieved.

The invention discloses a Lactobacillus. crispatus strain, and a microecological preparation thereof. The Lactobacillus. crispatus strain is Lactobacillus. crispatus IMC-159, possesses excellent H2O2 producing capacity, and excellent adhesive attraction on vaginal epithelial cells, and is capable of ensuring colonization of bacterial strains on vaginal epithelium. The Lactobacillus. crispatus IMC-159 possesses a certain application prospect in preventing and treating urogenital tract infection.

The invention relates to actobacillus jensenii and application thereof and particularly relates to Lactobacillus jensenii IMJ-118 for preventing and treating bacterial vaginosis. The strain has relatively strong capability of producing H2O2, and can effectively inhibit the growth of external pathogens and other conditional pathogenic bacteria; and meanwhile, the strain has a relatively strong adhesive effect against vaginal epithelial cells and ensures the colonization on vaginal epithelium. Thus, the Lactobacillus jensenii IMJ-118 provided by the invention has certain application prospects in the aspect of preventing and treating bacterial vaginosis.

The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.

The invention relates to an in-vitro culture method of vaginal epithelial cells of a mouse and belongs to the technical field of cell culture. According to the method, isolated vaginal tissue of the mouse is sheared into pieces in the size of 1 cm*0.5 cm, washed and subjected to overnight culture through Dispase II, the vaginal tissue subjected to overnight culture is separated, lamina propria tissue is discarded, epithelial layer tissue is mixed with 0.25% pancreatin and 0.02% EDTA (ethylene diamine tetraacetic acid) and digested, finally, digestion is stopped through DMEM (Dulbecco modified Eagle medium) / F12 containing 10% fetal calf serum, obtained cell suspension is filtered, centrifugalized, re-suspended with a PBS (phosphate buffer solution) and EPILIFE sequentially and put into a 5% CO2 culture box with the temperature of 37 DEG C to be cultured, and a solution is replaced for the first time after two days and is replaced once every two days later. The method is convenient to operate, a large quantity of cells are obtained, the purity is high, the activity is high, the cells can be subcultured for 4-5 generations stably, and seed cells can be provided for observation of physiological and pathological change and the cancerization process as well as establishment of tissue-engineered vaginas of vaginal epithelium.

The invention discloses a strain of Lactobacillus crispatus Lcr-MH175 used for preventing and treating urogenital tract infection in women, and its preservation number is CGMCC No.15938. The Lactobacillus crispatus Lcr-MH175 provided by the invention has strong antibacterial ability, can effectively inhibit the growth of foreign pathogenic bacteria and other conditional pathogenic bacteria; at the same time, it has strong adhesion to Hela cells, ensuring that the bacterial strain is Colonization of the vaginal epithelium. The Lactobacillus crispatus Lcr‑MH175 provided by the present invention has a certain application prospect in the prevention and treatment of urogenital tract infection.

The invention discloses a strain of Lactobacillus crispatus and its pharmaceutical application. The Lactobacillus flexus provided by the present invention is specifically Lactobacillus flexus IMC-105. The Lactobacillus flexus IMC-105 of the present invention has a strong ability to produce H2O2, and can effectively inhibit the growth of foreign pathogenic bacteria and other conditional pathogenic bacteria; At the same time, it has strong adhesion to vaginal epithelial cells, which ensures the colonization of bacterial strains in vaginal epithelial cells. The Lactobacillus flexus IMC‑105 provided by the present invention has a certain application prospect in the prevention and treatment of bacterial vaginosis.

The invention belongs to the field of biomedicines and discloses a construction method and application of a human normal vaginal epithelium 3D (Three Dimensional) differentiation culture model. A 2D (Two Dimensional) growth culture medium is provided and normal vaginal epithelial cells separated and cultured from normal tissues beside female vaginal cancer are obtained; any exogenous gene is not introduced and the normal vaginal epithelial cells have a physiological function of normal differentiation. The method for constructing the human normal differentiation vaginal epithelium 3D model comprises the following steps: re-suspending single cells by the 2D culture medium and inoculating the single cells into a gas-liquid culture device; replacing the growth culture medium with a differentiation culture medium and culturing for 14 to 21 days; after completely differentiating 3D gas-liquid culture of the human vaginal epithelial cells, inoculating HSV-2 (Herpes Simplex Virus-2) virus liquid to obtain an HSV-2 virus infection 3D model. The two types of 3D models can be used for physiological studies and drug toxicity safety evaluation of human normal reproductive tract epithelium, researches of pathogenic mechanisms of HSV-2 virus infected diseases and sexual transmission pathogen infected diseases and researches and development of anti-viruses medicines.

The invention discloses lactobacillus crispatus and application thereof. The perseveration number of the lactobacillus crispatus is as follows: CGMCC No.9388. The lactobacillus crispatus IMC-12 disclosed by the invention has relatively strong capacity of producing H2O2 and can be used for effectively inhibiting the growth of external pathogenic bacteria and other conditioned pathogenic bacteria and meanwhile, the lactobacillus cripatus has relatively strong adhesive attraction for vagina epithelial cells, so that the field planting of the vagina epithelial cell is guaranteed, and thus, the lactobacillus crispatus IMC-12 has certain application prospect in preventing and treating urogenital tract infection.

The invention provides a Lactobacillus reuteri and its application for preparing vaginal bacteriostatic drugs. The Lactobacillus reuteri is preserved in the General Microbiology Center of China Microbiological Culture Collection Management Committee, and its preservation number is CGMCC No.14110 . The study of its metabolic properties found that, compared with common Lactobacillus reuteri, this strain has stronger lactic acid production ability, hydrogen peroxide production ability, strong antibacterial ability to pathogenic bacteria, and prominent vaginal epithelial Cell adhesion ability. Based on the new properties discovered above, the present invention determines the new application of using it to prepare vaginal antibacterial drugs, which can realize the treatment of various bacterial vaginal diseases. The bacterial agent of the invention has remarkable effects on bacterial vaginal diseases, is safe, non-toxic, has good stability and can be stored for a long time, and also relates to its use in medicines for preventing and / or treating gynecological diseases.

A method and apparatus for vaginal rejuvenation are provided. The method of vaginal rejuvenation includes providing an injectable solution of amniotic membrane allograft. The solution is injected into a human female in a plurality of locations in a vaginal canal and introitus area to a depth immediately below a vaginal epithelium. A speculum includes at least one longitudinal member extending from an opening along a longitudinal axis and having a wall that curves about the axis having an inner surface and an outer surface, wherein the longitudinal member comprises multiple spaced portals extending through the wall. A kit includes the speculum and the injectable solution of amniotic membrane allograft.

The invention discloses Lactobacillus flexus for preventing and treating women's urogenital tract infection. The Lactobacillus campus provided by the present invention is specifically Lactobacillus campus (Lactobacillus. Growth of other conditional pathogenic bacteria; at the same time, it has strong adhesion to vaginal epithelial cells, ensuring the colonization of bacterial strains in vaginal epithelial cells. The Lactobacillus.crispatus IMC-25 provided by the present invention has a certain application prospect in the prevention and treatment of urogenital tract infection.

The invention discloses lactobacillus jensenii and application thereof. The lactobacillus jensenii is particularly lactobacillus jensenii IMJ-1, and the file No. of the lactobacillus jensenii IMJ-1 in the General Microbiological Culture Collection Center of China Microbial Culture Collection Management Committee is CGMCC No. 6558. The lactobacillus jensenii IMJ-1 CGMCC No.6558 has high H2O2 generation capability, can effectively suppress breeding of external pathogenic bacteria and other conditional pathogenic bacteria, and has a high binding function to epithelial cells of vagina, and accordingly, breeding of bacteria strains on the vaginal epithelium is guranteed. Besides, the lactobacillus jensenii IMJ-1 CGMCC No. 6558 has a certain application prospect in preventing and curing bacterial vaginosis.

The invention discloses a strain of Lactobacillus jansii and application thereof. Lactobacillus jensenii (Lactobacillus.jensenii) disclosed by the present invention is named as IMJ‑19, and has been preserved in the General Microorganism Center of China Microbiological Culture Collection Management Committee on July 14, 2014, and its preservation number is CGMCC No.9439 . Lactobacillus jensenii (Lactobacillus.jensenii) IMJ‑19 disclosed by the invention has a strong ability to produce H2O2, can effectively inhibit the growth of foreign pathogenic bacteria and other conditional pathogenic bacteria, and has a strong effect on the vaginal epithelium. The adhesion of the cells ensures the colonization of the strain on the vaginal epithelium, and Lactobacillus jensii IMJ‑19 has a certain application prospect in the prevention and treatment of urogenital tract infections.

The invention discloses a strain of Lactobacillus crispatus and its pharmaceutical application. The Lactobacillus flexus provided by the present invention is specifically Lactobacillus flexus IMC-79. The Lactobacillus flexus IMC-79 of the present invention has a strong ability to produce H2O2, and can effectively inhibit the growth of external pathogenic bacteria and other conditional pathogenic bacteria; At the same time, it has strong adhesion to vaginal epithelial cells, which ensures the colonization of bacterial strains in vaginal epithelial cells. The Lactobacillus flexus IMC-79 provided by the present invention has a certain application prospect in the prevention and treatment of bacterial vaginosis.

An intravaginal electrical stimulation device for treating pelvic pain in a female patient comprises a set of intravaginal components and an external controller. The intravaginal components include a frame, at least one pair of paracervical electrodes embedded in the proximal portion of the frame, an intravaginal capsule, an electrode plug that plugs into a socket in the proximal end of the capsule, and connecting wires that electrically couple the electrode plug to the paracervical electrodes. The intravaginal components are designed to inserted into the patient's vagina so that the paracervical electrodes are in direct contact with the vaginal epithelium in the lateral vaginal fornices. Electronics, including a microprocessor and an electrical stimulation generator, are configured to generate and transmit low-voltage electrical current to the paracervical electrodes to create an electrical field that neuromodulates the pelvic and paracervical nerves, the nerves that innervate the uterus, and other anatomical structures of the lower pelvis, which tends to reduce or eliminate pelvic pain. The set intravaginal components are configured so that a woman can easily insert them into her vagina (with or without a medical practitioner being present). The external controller, which communicates with the intravaginal components over a wireless data communication channel, sends instructions to and receives status updates from the microprocessor inside the intravaginal capsule. The external controller may be operated by the female patient to control the electrical profile (e.g., frequency, amplitude and duration) of the electrical stimulation delivered to her body, and thereby cause the intravaginal components to deliver well-controlled, personalized, electrical stimulation to her pelvic and paracervical nerves when she is experiencing pain, or when she anticipates the onset of pelvic pain due to, for example, menstruation or sexual intercourse.

The invention discloses lactobacillus crispatus and a pharmaceutical application thereof. The lactobacillus crispatus provided by the invention is lactobacillus crispatus IMC-105 which has relatively strong capability of producing H2O2 and can effectively inhibit the growth of foreign pathogens and other conditioned pathogens; and meanwhile, the lactobacillus crispatus IMC-105 also has relatively strong effect of adhering vaginal epithelial cells, thereby ensuring the fix planting of strains on vaginal epithelium. The lactobacillus crispatus IMC-105 provided by the invention has a certain application prospect in prevention and treatment of bacterial vaginal diseases.

The invention relates to Lactobacillus jensenii and application thereof, in particular to Lactobacillus jensenii IMJ‑118 used for preventing and treating bacterial vaginosis. The strain has a strong production of H 2 o 2 The ability to effectively inhibit the growth of foreign pathogens and other conditional pathogens; at the same time, it has a strong adhesion to vaginal epithelial cells, ensuring the colonization of bacterial strains in the vaginal epithelium. Therefore, the Lactobacillus jansii IMJ‑118 provided by the present invention has a certain application prospect in the prevention and treatment of bacterial vaginosis.

The invention discloses a traditional Chinese medicine lotion for treating gynecological vaginitis and a preparation method thereof. The traditional Chinese medicine lotion is prepared from saffron crocus, honeysuckle, aloe, folium artemisiae argyi, the tuber of stemona, japanese conehead herb, herba eupatorii lindleyani, radix sophorae flavescentis, felwort, panax notoginseng, fiveleaf akebia fruit, corydalis tuber, lotus plumule, cape jasmine, rhizoma alismatis, corn stigma and folium ginkgo. The preparation method comprises the following steps: weighing the various traditional Chinese medicine raw materials according to a ratio, cleaning and airing; adding water, decocting twice, merging the decoction twice, filtering, concentrating the filtrate into clear paste, adding ethanol for extracting, standing and filtering, concentrating and evaporating to recover the ethanol, thereby obtaining the product. The compatibility of the medicines is reasonable, and the prepared traditional Chinese medicine lotion disclosed by the invention has the pharmacological actions of broad spectrum, high efficiency, inflammation diminishment and pain relief, itching relief and anti-trichomonad effect, can achieve the effects of promoting vaginal epithelium synthesis and secretion of glycogens, promoting production of vaginal lactobacillus and restoring a normal vaginal ecological system, can be used for treating colpitis mycotica and general vaginitis, and has the advantages of obvious curative effect, zero side effect and low reoccurrence rate.